| abstract |
The present invention relates to an insulin analogue having a reduced insulin receptor-mediated clearance rate, compared to native insulin, and an insulin analogue conjugate thereof. Further, the present invention relates to a long-acting insulin analogue formulation using the insulin analogue or the conjugate thereof, a long-acting formulation for preventing or treating diabetes including the conjugate, and a long-acting formulation for preventing or treating diabetes including the insulin analogue or the conjugate thereof; and an insulinotropic peptide or a derivative thereof. Furthermore, the present invention relates to a method for treating diabetes using the insulin analogue, the conjugate thereof, the long-acting insulin formulation, or the long-acting formulation for preventing or treating diabetes. The insulin analogue of the present invention has a reduced insulin receptor-mediated clearance rate to have a increased blood half-life, compared to native insulin, thereby providing an insulin analogue conjugate and a long-acting formulation capable of increasing in-vivo half-life and bioavailability, and/or maintaining activity. Accordingly, dosing convenience for patients with various insulin-related diseases is increased to remarkably improve drug compliance. |